35 CluntunA
By inhibiting the NP (natriuretic peptide) system, sacubitril/valsartan increases natriuretic peptides (NPs) levels that, in turn, lead to vasodilation, natriuresis and RAAS inhibition through intracellular cyclic guanosine monophosphate (cGMP)-dependent pathways
This patient was included in the study from February 2022 to July 2023 and counted as having a first-time GLP-1 RA prescription in July 2023
GLP-1 Drugs: The Strongest Path to Lasting Weight Loss & Improvement in Related Health Conditions September 12, 2025 By: Janet Klein, MS, RDN, CDN, CDCES Categories: Bariatric, Blog, Health & Wellness Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director It may not be much of a surprise to hear that with the increased use of GLP-1s for weight loss, there has been a noted decline in patients undergoing bariatric surgery